Ensysce Biosciences Reports Second Quarter 2026 Financial Results and ...
(PR-inside.com) Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Bio…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


